Cyp3a Inducers Interactions

Strong inducers of UGT1A1 decrease cabotegravir plasma concentrations and may result in loss of virologic response.

Source: NLP:cabotegravir and rilpivirine

Strong CYP3A inducers significantly decrease lenacapavir plasma concentrations, resulting in loss of therapeutic effect and development of resistance.

Source: NLP:lenacapavir sodium

Strong CYP3A inducers are contraindicated with lorlatinib. Concomitant use decreases lorlatinib plasma concentrations, which may decrease efficacy.

Source: NLP:lorlatinib

Co-administration decreases mitapivat plasma concentrations, reducing efficacy of PYRUKYND. Avoid concomitant use.

Source: NLP:mitapivat

Concomitant use decreases defactinib exposure, which may reduce the effectiveness of the drug combination. Avoid concomitant use.

Source: NLP:avutometinib potassium and defactinib hydrochloride

Coadministration with strong CYP3A inducers decreased capmatinib exposure, which may decrease TABRECTA anti-tumor activity. Avoid coadministration.

Source: NLP:capmatinib

Coadministration may decrease dasatinib concentrations and reduce efficacy. Consider alternative drugs or dasatinib dose increase.

Source: NLP:dasatinib

Concomitant use decreases imlunestrant exposure, which may reduce effectiveness. Avoid concomitant use; if unavoidable, increase imlunestrant dosage.

Source: NLP:imlunestrant

Strong CYP3A4 inducers decrease ribociclib plasma exposure, potentially reducing efficacy. Coadministration should be avoided.

Source: NLP:letrozole and ribociclib

Concomitant use is contraindicated. Strong inducers decrease mavorixafor Cmax and AUC, reducing drug effectiveness.

Source: NLP:mavorixafor

Concomitant use decreases nilotinib concentrations, which may reduce nilotinib efficacy. Avoid concomitant use.

Source: NLP:nilotinib

Strong CYP3A4 inducers may decrease abiraterone concentrations, which may reduce the effectiveness of abiraterone.

Source: NLP:niraparib tosylate monohydrate and abiraterone acetate

Co-administration decreases palovarotene exposure, which may reduce effectiveness of SOHONOS. Avoid concomitant use.

Source: NLP:palovarotene

Concomitant use decreases remibrutinib exposure and may decrease efficacy. Avoid concomitant use.

Source: NLP:remibrutinib

Concomitant use may decrease repotrectinib plasma concentrations and reduce efficacy of AUGTYRO. Avoid concomitant use.

Source: NLP:repotrectinib

Coadministration decreases ripretinib and active metabolite exposure, which may decrease anti-tumor activity. Avoid concomitant use.

Source: NLP:ripretinib

Reduces exposure to tolvaptan. Avoid concomitant use.

Source: NLP:tolvaptan

May decrease tretinoin plasma concentrations and reduce its efficacy. Avoid concomitant use if possible.

Source: NLP:tretinoin

Avoid concomitant use. May decrease ziftomenib exposure and reduce efficacy of KOMZIFTI.

Source: NLP:ziftomenib

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers.

Source: NLP:amlodipine and atorvastatin

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers due to potential decreased amlodipine efficacy.

Source: NLP:amlodipine and valsartan

Co-administration with amlodipine may reduce amlodipine efficacy. Closely monitor blood pressure when co-administered.

Source: NLP:amlodipine and olmesartan medoxomil

Prolonged or accelerated half-life of metronidazole or concomitant medications; use with caution.

Source: NLP:bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride

Coadministration decreases bortezomib exposure, which may decrease efficacy. Avoid concomitant use.

Source: NLP:bortezomib

Concomitant use decreases buprenorphine plasma concentration, potentially resulting in decreased efficacy or withdrawal syndrome. Discontinuation may cause serious respiratory depression.

Source: NLP:buprenorphine hcl

Concomitant use decreases crinecerfont exposure, which may reduce efficacy. Requires 2-fold increase in morning and evening dosage.

Source: NLP:crinecerfont

Coadministration decreases entrectinib plasma concentrations, which may reduce ROZLYTREK efficacy. Avoid coadministration.

Source: NLP:entrectinib

Concomitant use of strong CYP3A inducers decreases eravacycline exposure, which may reduce efficacy. XERAVA dose increase required.

Source: NLP:eravacycline

CYP3A4 inducers decrease haloperidol exposure and may reduce the effectiveness of haloperidol decanoate. Monitor patients and increase dosage if necessary.

Source: NLP:haloperidol decanoate

Decrease plasma concentration of oxycodone, resulting in decreased efficacy or withdrawal syndrome. Stopping inducers may increase oxycodone concentration and risk of respiratory depression.

Source: NLP:oxycodone hydrochloride

Inducers may decrease phenobarbital exposure, reducing efficacy and increasing risk of breakthrough seizures. Closely monitor and consider dosage adjustment.

Source: NLP:phenobarbital sodium

Inducers of CYP3A4 may decrease ruxolitinib systemic concentrations, potentially reducing efficacy.

Source: NLP:ruxolitinib

Co-administration may decrease sunitinib plasma concentrations. Consider dose increase of sunitinib malate.

Source: NLP:sunitinib malate